Live feed07:00:00·31dPRReleasevia QuantisnowKaryopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume ReductionByQuantisnow·Wall Street's wire, on your screen.KPTI· Karyopharm Therapeutics Inc.Health CareOriginal source
